Tom van Meerten, MD, PhD

Tom van Meerten, MD, PhD, outlines select patient subgroups with BTK inhibitor–naive relapsed/refractory MCL who may benefit from treatment with brexu-cel.

Tom van Meerten, MD, PhD, discusses the role of brexucabtagene autoleucel in high-risk MCL.

Tom van Meerten, MD, PhD, discusses the efficacy and safety of brexucabtagene autoleucel in BTK inhibitor–naive relapsed/refractory MCL.